Ribeiro MFSA, Gadotti LL, Sacardo KP, Lopes CDH, Saddi R, Alessi JVM, de Macedo MP, do Nascimento ECT, Testagrossa LDA, Katz A. Unique
SLC12A2-ROS1 fusion is associated with marked response to crizotinib in lung adenocarcinoma.
SAGE Open Med Case Rep 2022;
10:2050313X221100407. [PMID:
35619747 PMCID:
PMC9127844 DOI:
10.1177/2050313x221100407]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Accepted: 04/21/2022] [Indexed: 11/17/2022] Open
Abstract
Chromosomal rearrangements involving the c-ros oncogene 1 (ROS1) gene define a subset of non-small cell lung cancers highly sensitive to small-molecule tyrosine kinase inhibitors. However, little is known about the impact of different fusion partners on tyrosine kinase inhibitor efficacy. We herein describe a case of a 26-year-old never-smoker patient from southern Africa with metastatic lung adenocarcinoma driven by SLC12A2-ROS1 fusion, who had a pronounced and durable response to crizotinib. The present case underscores the importance of pursuing actionable alterations in patients with similar clinical and epidemiological characteristics. In addition, provides the second report of crizotinib activity against lung malignancies harboring the unique SLC12A2-ROS1 fusion and highlights the importance of a deeper understanding of molecular alterations in underrepresented subgroups of patients to tailor the decision-making in daily practice.
Collapse